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Intranasal (i.n.), but not oral, immunization of mice with inactivated rotavirus induces protection against challenge. To
understand the mechanisms by which i.n. immunization with inactivated rotavirus evokes protective immunity, we examined
the site of rotavirus-specific B cell activation and the origins of intestinal IgA-secreting B cells following i.n. inoculation of
mice with inactivated rhesus rotavirus. We found that (1) i.n., but not oral, inoculation induced partial protection after
challenge; (2) i.n., but not oral, inoculation induced production of rotavirus-specific IgM, IgA, and IgG by intestinal lymphoid
tissues; and (3) after i.n. inoculation, nasal-associated lymphoid tissues (NALT) and bronchial lymph nodes (BLN) were the
sites of initial production of rotavirus-specific antibodies. These studies indicate that after inoculation with inactivated
rotavirus, virus-specific effector B cells may be more easily activated in respiratory, compared to intestinal, lymphoid tissues.
Additional studies are needed to determine if these observations are due to fundamental differences in the microenvironment
of NALT and BLN compared to Peyer’s patches or are a function of the anatomic differences between the respiratory and
the gastrointestinal tracts. © 2001 Elsevier Science
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Recent studies have demonstrated that intestinal im-
munity may be induced by intranasal (i.n.) inoculation
with nonreplicating immunogens (Choi et al., 1999; Mc-
Neal et al., 1999; Morris et al., 2000; O’Neal et al., 1998).
Inactivated rotavirus (McNeal et al., 1999), purified rota-
virus proteins (Choi et al., 1999), and rotavirus virus-like
particles (VLP) (O’Neal et al., 1998) have all been shown
to evoke fecal antibodies or protection against chal-
lenge. In contrast, oral inoculation with inactivated rota-
virus may require large doses of viral protein (Khoury et
al., 1995; McNeal et al., 1999), multiple inoculations (Mc-
Neal et al., 1999), or the use of adjuvants (Khoury et al.,
1995; McNeal et al., 1999) to stimulate intestinal immu-
nity. These observations suggest that fundamental differ-
ences may exist in the inductive tissues of respiratory-,
compared to gut-, associated lymphoid tissues. Alterna-
tively, anatomic differences in the respiratory and intes-
tinal tissues may account for these findings.
At present, little is known about the mechanisms by
which i.n. immunization stimulates intestinal immunity.
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dressed at the Division of Immunologic and Infectious Diseases,
The Children’s Hospital of Philadelphia, 34th Street and Civic
Center Boulevard, Philadelphia, PA 19104. Fax: (215) 590-2025. E-mail:
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235Similarly, the inductive sites within respiratory-associ-
ated lymphoid tissues (RALT) remain undefined (Bienen-
stock et al., 1999). In this report, we investigate the site of
virus-specific B cell activation and the origins of intesti-
nal IgA-secreting B cells following i.n. inoculation with
inactivated rotavirus.
RESULTS
Relative capacity of oral or i.n. immunization
to protect against challenge
Initially, we evaluated the relative capacity of oral or
i.n. immunization of mice with live or inactivated rotavirus
to protect against challenge. Four weeks after oral or i.n.
immunization with equivalent doses of live or inactivated
rhesus rotavirus, strain RRV, mice were challenged orally
with wild-type murine rotavirus, strain EDIM. We found
that i.n., but not oral, immunization with inactivated rota-
virus induced partial protection against fecal viral shed-
ding after challenge (Fig. 1). A 70% reduction in the total
quantity of fecal virus shed was observed in mice immu-
nized i.n. with inactivated RRV compared to buffer (P ,
0.05). Equivalent quantities of viral antigen were shed by
mice inoculated orally with inactivated rotavirus com-
pared to mice inoculated i.n. with buffer (P 5 0.66). Oral
or i.n. immunization with live rotavirus induced complete
or near-complete protection from viral shedding follow-
ing challenge.
0042-6822/01 $35.00
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236 COFFIN AND CLARKInduction of virus-specific antibody production by
intestinal lymphoid tissues after oral or i.n. inoculation
We examined the relative capacity of oral or i.n. inoc-
ulation with live or inactivated rotavirus to induce the
production of rotavirus-specific antibodies by intestinal
lymphoid tissues. Four weeks after oral inoculation with
live or inactivated rotavirus, comparable quantities of
rotavirus-specific IgA and IgG were produced by small
intestinal lamina propria (LP) lymphocytes (Table 1).
However, rotavirus-specific antibodies were produced by
LP lymphocytes harvested from mice inoculated i.n., but
not orally, with inactivated RRV. Lesser quantities of ro-
tavirus-specific IgA were produced by LP lymphocytes
from mice inoculated i.n. with inactivated rotavirus than
from mice inoculated orally with live virus (P , 0.05).
Quantities of rotavirus-specific IgG produced by LP lym-
phocytes from mice inoculated i.n. with live or inactivated
rotavirus were not significantly different from those pro-
duced by mice inoculated orally with live rotavirus. In this
study, we found that protection from challenge was more
closely correlated with intestinal production of virus-
specific IgG than IgA (correlation coefficients 20.89 and
20.69, respectively). Serum rotavirus-specific IgA and
IgG were detected in mice inoculated i.n., but not orally,
with inactivated RRV (Table 2). Quantities of serum rota-
virus-specific antibodies from mice inoculated i.n. with
inactivated rotavirus were less than those found in mice
inoculated i.n. or orally with live RRV.
Site of induction of rotavirus-specific antibodies after
i.n. inoculation with inactivated rotavirus
FIG. 1. Mean quantities of rotavirus antigen shed in feces after
challenge of mice previously immunized with live or inactivated rota-
virus. Four weeks after i.n. or oral inoculation with live rhesus rotavirus
(RRV) or inactivated rhesus rotavirus (iRRV), five mice per group were
challenged orally with EDIM. Fecal pellets were collected from individ-
ual mice daily for 7 days. Individual fecal suspensions (10% wt/vol)
were tested for the presence of viral antigen by ELISA. Error bars,
standard errors of the mean.To identify possible sites of rotavirus-specific B cell
activation, we evaluated the kinetics of mucosal antibodyproduction following i.n. inoculation with inactivated ro-
tavirus. We found that B cells present in RALT produced
rotavirus-specific IgA 6 days earlier than intestinal B
cells (Table 3). Initial production of virus-specific IgA by
TABLE 1
Quantities of Intestinal Rotavirus-Specific IgA and IgG Produced 4
Weeks after Intranasal or Oral Inoculation of Mice with Live or
Inactivated Rotavirusa
Antigenb Dosec Route
Virus-specific
IgA (ng/ml)d
Virus-specific
IgG (ng/ml)
iRRV 350 ng p.o. ,0.5 ,0.5
RRV 2 3 107 PFU p.o. 12.4 6 2.6 13.6 6 1.8
iRRV 350 ng i.n. 2.2 6 0.8e 19.9 6 2.5NS
RRV 2 3 107 PFU i.n. 27.1 6 4.5NS 22.3 6 1.2NS
Buffer 100 ml i.n. ,0.5 ,0.5
Note. NS, not statistically significant (P . 0.05) compared with mice
inoculated p.o. with live RRV.
a Four weeks after oral or i.n. inoculation with live or inactivated
rotavirus, small intestinal lamina propria organ cultures were estab-
lished using three mice per group. Supernatants were tested for the
presence of rotavirus-specific IgA and IgG by ELISA.
b Antigens used were inactivated rhesus rotavirus (iRRV) and live
rhesus rotavirus (RRV).
c Mice were inoculated with equivalent quantities of live (2 3 107
PFU or 350 ng) or inactivated (350 ng) rotavirus.
d Concentration of rotavirus-specific antibodies (ng/ml) 6 standard
error of the mean.
e P , 0.05 compared with mice inoculated with buffer.
TABLE 2
Geometric Mean Endpoint Titers of Serum Rotavirus-Specific IgA
and IgG Detected 4 Weeks after Intranasal or Oral Inoculation of
Mice with Live or Inactivated Rotavirusa
Antigenb Dose Route
Virus-specific
IgAc
Virus-specific
IgG
iRRV 350 ng p.o. ,50 ,50
RRV 2 3 107 PFUd p.o. 602e
(326–3304)
44,572e
(18,665–98,932)
iRRV 350 ng i.n. 200e
(86–467)
25,600e
(6,810–79,322)
RRV 2 3 107 PFU i.n. 1202e,f
(478–3073)
102,400e,f
(33,554–238,400)
Buffer 100 ml i.n. ,50 ,50
a Mice were bled by retro-orbital puncture 4 weeks after oral or i.n.
inoculation with live or inactivated rotavirus. Sera were tested for the
presence of rotavirus-specific IgA and IgG by ELISA.
b Antigens used were inactivated rhesus rotavirus (iRRV) and live
rhesus rotavirus (RRV).
c Geometric mean endpoint titer of rotavirus-specific antibodies. 95%
confidence intervals are included in parentheses.
d Mice were inoculated with equivalent quantities of live (2 3 107
PFU or 350 ng) or inactivated (350 ng) rotavirus.
e P , 0.05 compared with mice inoculated with buffer.
f P , 0.05 compared with mice inoculated i.n. with iRRV.
237INTRANASAL IMMUNIZATION WITH INACTIVATED ROTAVIRUSnasal-associated lymphoid tissues (NALT) and bronchial
lymph nodes (BLN) occurred 4 days after i.n. inoculation.
Seven days after i.n. inoculation, significant quantities of
virus-specific IgA were produced by cervical lymph
nodes (CLN). Virus-specific IgA was not produced by
intestinal lymphoid tissues until 10 days after i.n. inocu-
lation. Production of rotavirus-specific IgG by intestinal
lymphoid tissues was also delayed compared to produc-
tion by RALT (Table 4).
DISCUSSION
Other investigators have also observed that i.n. immu-
nization with inactivated rotavirus (McNeal et al., 1999),
purified rotavirus proteins (Choi et al., 1999), or rotavirus
VLP (O’Neal et al., 1998) induced fecal rotavirus-specific
antibodies and protection against challenge. In addition,
previous studies have demonstrated that inactivated ro-
tavirus is poorly immunogenic when administered orally;
large quantities of viral antigen, booster doses, viral
microencapsulation, or adjuvant were required to induce
intestinal virus-specific antibody responses (Khoury et
al., 1995; McNeal et al., 1999). Our work extends these
TABLE 3
Quantities of Rotavirus-Specific IgA Produced by Respiratory and
Intestinal Lymphoid Tissues Following Intranasal Inoculation of Mice
with Inactivated Rotavirusa
Day 2 Day 4 Day 7 Day 10 Day 14
NALTb ,0.5c 2.5 6 2.0
(0.38)d
4.4 6 1.9
(0.56)
4.9 6 2.2
(2.34)
2.4 6 1.9
(1.14)
CLN ,0.5 ,0.5 11.7 6 3.1
(0.58)
3.6 6 2.5
(0.31)
4.6 6 2.5
(1.41)
BLN ,0.5 2.2 6 1.3 8.1 6 1.6
(0.87)
11.4 6 4.8
(3.10)
10.3 6 4.7
(1.41)
LUNG ,0.5 ,0.5 ,0.5 0.8 6 0.6
(1.05)
3.8 6 2.1
(4.36)
PP ,0.5 ,0.5 ,0.5 1.4 6 1.2
(0.07)
1.0 6 0.6
(0.06)
MLN ,0.5 ,0.5 ,0.5 ,0.5 ,0.5
LP ,0.5 ,0.5 ,0.5 1.8 6 0.7
(,0.01)
1.7 6 0.6
(,0.01)
a Mice were inoculated i.n. with inactivated rhesus rotavirus. Two to
14 days following inoculation, three mice per group per time point were
sacrificed and lymphoid organ cultures were established. Organ cul-
ture supernatants were tested for the presence of rotavirus-specific IgA
by ELISA. ELISA was unable to detect rotavirus-specific antibodies at
a concentration of ,0.5 ng/ml.
b Tissues tested: NALT, nasal-associated lymphoid tissues; CLN,
cervical lymph nodes; BLN, bronchial lymph nodes; PP, Peyer’s
patches; MLN, mesenteric lymph nodes; LP, small intestinal lamina
propria.
c Concentration of rotavirus-specific IgA (ng/ml) 6 standard error of
the mean.
d Percentage of rotavirus-specific IgA/total IgA.findings by comparing the relative efficiencies of primary
i.n. or oral immunization with inactivated rotavirus in theabsence of adjuvant to induce protection against chal-
lenge and production of rotavirus-specific antibodies by
mucosal lymphocytes. Although i.n. administration of a
100-ml inoculum would likely result in a combined oral-
respiratory immunization, we do not suspect that unrec-
ognized aspiration of the immunogen into the intestinal
tract altered the pattern of virus-specific immune re-
sponses we detected after i.n. inoculation with inacti-
vated rotavirus. Taken together, these observations sug-
gest that activation and differentiation of antigen-specific
B cells by nonreplicating immunogens may occur more
efficiently in respiratory-, compared to gut-, associated
lymphoid tissues. This phenomenon may be due to an-
atomic or immunologic differences in the respiratory,
compared to intestinal, tract.
We found that NALT, BLN, and CLN were sites of early
production of rotavirus-specific antibodies. Our data sug-
gest that rotavirus-specific antibody-secreting B cells
may originate in RALT and then traffic from RALT to
intestinal lymphoid tissues after i.n. inoculation with in-
activated rotavirus. Greenberg and coworkers have dem-
onstrated that resolution of rotavirus infection is associ-
ated with homing of a4b7-bearing memory B and T cells
to the intestine (Rose et al., 1998; Williams et al., 1998).
TABLE 4
Quantities of Rotavirus-Specific IgG Produced by Respiratory and
Intestinal Lymphoid Tissues Following Intranasal Inoculation of Mice
with Inactivated Rotavirusa
Day 2 Day 4 Day 7 Day 10 Day 14
NALTb ,0.5c ,0.5 2.8 6 1.1
(3.59)d
2.7 1 2.0
(2.97)
3.9 6 1.9
(4.27)
CLN ,0.5 ,0.5 8.9 6 4.6
(1.39)
14.0 6 4.8
(3.63)
34.7 6 8.5
(9.13)
BLN ,0.5 28.1 6 15.0
(2.73)
35.9 6 46.5
(0.45)
29.0 6 29.0
(1.41)
12.3 6 2.8
(0.60)
LUNG ,0.5 ,0.5 6.5 6 1.5
(6.02)
36.5 6 4.4
(21.98)
30.2 6 8.4
(17.76)
PP ,0.5 ,0.5 10.1 6 3.9
(1.01)
10.4 6 1.1
(0.35)
14.5 6 2.7
(0.52)
MLN ,0.5 ,0.5 16.7 6 6.2
(2.09)
31.1 6 3.7
(2.83)
54.3 6 8.6
(2.86)
LP ,0.5 ,0.5 11.8 6 4.6
(0.01)
42.4 6 5.2
(0.04)
56.2 6 4.9
(0.04)
a Mice were inoculated i.n. with inactivated rhesus rotavirus. Two to
14 days following inoculation, three mice per group per time point were
sacrificed and lymphoid organ cultures were established. Organ cul-
ture supernatants were tested for the presence of rotavirus-specific
IgG by ELISA. ELISA was unable to detect rotavirus-specific antibodies
at a concentration of ,0.5 ng/ml.
b Tissues tested: NALT, nasal-associated lymphoid tissues; CLN,
cervical lymph nodes; BLN, bronchial lymph nodes; PP, Peyer’s
patches; MLN, mesenteric lymph nodes; LP, small intestinal lamina
propria.
c Concentration of rotavirus-specific IgA (ng/ml) 6 standard error of
the mean.
d Percentage of rotavirus-specific IgG/total IgG.
238 COFFIN AND CLARKAlternatively, viral immunogens may disseminate from
the site of inoculation to gut-associated lymphoid tissues
through the systemic circulation. However, this hypothe-
sis is unlikely given the inability of inactivated virus to
stimulate production of virus-specific antibodies after
oral inoculation. Although the anatomic location of anti-
gen presentation within RALT remains obscure, our find-
ings indicate that rotavirus antigens may be presented
within NALT, BLN, or both following i.n. inoculation with
inactivated virus. We presume that i.n. immunization with
inactivated rotavirus induced activated virus-specific B
cells to emigrate from RALT, enter the systemic circula-
tion, and then disseminate to distant mucosal sites
through the expression of mucosal homing receptors,
such as a4b7. Alternatively, virus-specific antigen-pre-
senting cells (APC) may be generated in RALT and then
traffic to intestinal tissues as we have previously de-
scribed after intramuscular inoculation with rotavirus
(Coffin et al., 1999). Adoptive transfer studies are in
progress to define further the respiratory tissue of origin,
cell type, and homing receptors that give rise to intestinal
virus-specific IgA-secreting cells following i.n. inocula-
tion with inactivated rotavirus.
Several hypotheses may explain why i.n., but not oral,
immunization induced virus-specific humoral immune re-
sponses and partial protection after inoculation with in-
activated rotavirus. First, anatomic differences in the
respiratory, compared to the intestinal, tract may facili-
tate uptake of small quantities of nonreplicating viral
antigens. To induce immunity, orally administered vac-
cines must survive dilution by intestinal fluids, degrada-
tion by gastric acid, and expulsion by peristalsis. In
addition, we cannot exclude the possibility that inacti-
vated, compared to live, rotavirus was more sensitive to
the degradative effects of stomach acid. However, pso-
ralen–UV light inactivation has been shown to have little
effect on viral capsid proteins (Groene and Shaw, 1992).
Second, expansion of antigen through replication may be
required to evoke virus-specific immune responses after
oral inoculation with small doses of virus. Whereas large
quantities of orally administered nonreplicating immuno-
gens can induce mucosal and systemic immune re-
sponses (Ball et al., 1998; Khoury et al., 1995; McNeal et
al., 1999; O’Neal et al., 1997), lower doses of similar
immunogens may require the use of mucosal adjuvants
(Khoury et al., 1995; McNeal et al., 1999; To et al., 1998) or
booster dosing (To et al., 1998). Third, oral administration
of a single, low dose of a nonreplicating agent, such as
inactivated rotavirus, may induce tolerance (Mowat and
Weiner, 1999), while the factors required to induce toler-
ance after i.n. inoculation may differ. Fourth, APC resi-
dent in inductive tissues within respiratory tissues may
process and present viral immunogens more efficiently
than those resident within intestinal inductive tissues.
For example, alterations in the type of APC responsiblefor antigen presentation may influence mucosal humoral
immune responses and protection (Coffin et al., 1999).
Finally, different immunologic effector functions may me-
diate intestinal protection induced by i.n. inoculation.
Other investigators have correlated rotavirus-specific in-
testinal IgG (O’Neal et al., 1998) or antibody-independent
mechanisms (Choi et al., 1999) with protection from oral
challenge. In this study, we found that protection from
challenge was more closely correlated with intestinal
production of virus-specific IgG than with IgA. Thus, i.n.
inoculation may facilitate the uptake of relatively small
quantities of nonreplicating immunogens or select for
critical populations of APC.
In summary, we found that i.n., but not oral, inoculation
with inactivated rotavirus induced production of intesti-
nal rotavirus-specific antibodies and protection against
challenge. In addition, intestinal rotavirus-specific B cell
responses originated in respiratory lymphoid tissues fol-
lowing i.n. inoculation. Finally, our studies suggest that
NALT or BLN or both may be sites of immunologic
induction following i.n. inoculation of mice. Additional
studies are under way to define the mechanisms by
which antigen-specific antibody responses are induced
by i.n. inoculation.
MATERIALS AND METHODS
Mice
Conventionally reared, 5- to 8-week-old BALB/c female
mice (Taconic Breeding Laboratories, Germantown, NY)
were housed in individual isolation units. Prior to inocu-
lation, sera from these mice did not contain rotavirus-
specific antibodies as determined by ELISA.
Viruses
Rhesus rotavirus, strain RRV, was originally obtained
from N. Schmidt (Viral and Rickettsial Disease Labora-
tory, Berkeley, CA). RRV was grown in MA104 cells and
infectivity was quantitated by plaque assay as described
previously (Offit et al., 1983). RRV was inactivated by
treatment with psoralen (HRI Associates, Concord, CA)
and UV light as previously described (Coffin et al., 1997;
Groene and Shaw, 1992). Inactivated virus contained ,5
PFU/ml. Murine rotavirus, strain EDIM, was originally
obtained from Richard Ward (Children’s Hospital of Cin-
cinnati, Cincinnati, OH) and passaged in infant mice as
previously described (Coffin et al., 1999).
Immunization of mice
Mice were lightly anesthetized with ketamine and xy-
lazine and inoculated orally or i.n. with 100-ml volumes of
7equivalent doses of live (2 3 10 PFU) or inactivated (350
ng) RRV.
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Four weeks after immunization, mice were challenged
orally with 2.4 3 105 50% shedding dose of wild-type EDIM.
Two fecal pellets were collected daily from five mice per
group for 7 days after challenge. Fecal suspensions (10%
wt/vol) were tested for the presence of rotavirus antigen by
ELISA (Coffin et al., 1997; Ward et al., 1990).
Lymphoid organ cultures
Respiratory and intestinal lymphoid organ cultures were
performed to assess production of rotavirus-specific anti-
bodies by mucosal lymphoid tissues using previously de-
scribed techniques (Coffin et al., 1999; Logan et al., 1991).
Respiratory tissues harvested for culture included (1) nasal-
associated lymphoid tissue, (2) cervical lymph nodes, (3)
bronchial lymph nodes, and (4) lung. NALT was harvested
from the superior aspect of the murine hard palate as
described by Asanuma and coworkers (1995). Intestinal
lymphoid tissues cultured included (1) Peyer’s patches, (2)
mesenteric lymph nodes, or small intestinal lamina propria
fragments. Samples were incubated at 37°C in an atmo-
sphere of 95% O2 and 5% CO2 for 5 days in 500 ml of
medium. Cultures were established 2, 4, 7, 10, 14, or 28 days
after primary inoculation. After 5 days of culture, superna-
tant fluids from individual wells were collected and stored
at 220°C prior to testing for the presence of rotavirus-
specific immunoglobulins (IgM, IgA, and IgG) by ELISA.
Previously performed kinetic studies demonstrated that Ig’s
detected in supernatant fluids of lymphoid organ cultures
were generated in vitro and did not arise from passive
transudation of serum-derived antibodies (Logan et al.,
1991; Coffin et al., 1995).
Detection of rotavirus-specific and total
immunoglobulins by ELISA
Supernatant fluids from intestinal and respiratory lym-
phoid organ cultures were tested for the presence of
rotavirus-specific and total IgM, IgA, and IgG (Khoury et
al., 1994). Quantities of total IgM, IgA, and IgG were
determined to ensure the viability of each organ culture.
Serial dilutions of isotype-specific standards were run
with each assay. A standard curve was constructed and
used to determine the concentration of virus-specific
antibodies present in supernatant fluids. Concentrations
of serum rotavirus-specific antibodies were determined
by ELISA using serial twofold dilutions of serum speci-
mens. The final dilution that tested positive was identi-
fied as the endpoint titer of a given specimen.
Detection of rotavirus antigen in fecal specimens
by ELISA
Fecal suspensions were tested for the presence of
rotavirus antigen by ELISA as previously described (Cof-
fin et al., 1997).Statistical analysis
Student’s t tests were performed to determine statis-
tical differences in antibody or antigen concentrations.
P values less than 0.05 were considered significant.
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